CROI 2015 Program and Abstracts

Poster Listings

Session P-G2 Poster Session

Poster Hall

450 Neurocognition Following Antiretroviral Initiation in Behaviorally HIV- Infected Youth Sharon Nichols 1 ; Patricia Garvie 2 ;Tiandong Li 3 ;Weijia Ren 3 ; Bill Kapogiannis 4 ; Bret Rudy 5 ; John Sleasman 6 ; StevenWoods 7 ; Ana Puga 2 The Adolescent MedicineTrials Network for HIV/AIDS Interventions 1 University of California San Diego, La Jolla, CA, US; 2 Children’s Diagnostic & Treament Center, Inc., Ft. Lauderdale, FL, US; 3 Westat, Inc., Rockville, MD, US; 4 National Institutes of Health (NIH), Bethesda, MD, US; 5 New York University, New York, NY, US; 6 Duke University, Durham, NC, US; 7 University of California, San Diego, La Jolla, CA, US

2:30 pm– 4:00 pm Optimizing ART for HAND Treatment and Prevention 441 Maraviroc-Enhanced CART Improves Cognition in Virally Suppressed HAND: A Pilot Study Thomas M. Gates 1 ; Lucette A. Cysique 2 ; Joga Chaganti 1 ; Krista J. Siefried 1 ; Bruce J. Brew 1 1 St Vincent’s Hospital, Sydney, Sydney, Australia; 2 Neuroscience Research Australia (NeuRA), Sydney, Australia 442 Similar Neurocognitive Performance in Patients on ATV/r Monotherapy vs Triple Therapy Giada Caramatti 1 ; Francesca Ferretti 1 ; Antonio Di Biagio 2 ; Amedeo Capetti 3 ; Andrea Antinori 4 ; Fiorella Di Sora 5 ; Roberta Gagliardini 6 ; ConcettaVinci 1 ; Adriano Lazzarin 1 ; Laura Galli 1 1 San Raffaele Scientific Institute, Milan, Italy; 2 Azienda Ospedaliera San Martino, Genoa, Italy; 3 L. Sacco University Hospital, Milan, Italy; 4 National Institute for Infectious Diseases IRCCS Lazzaro Spallanzani, Rome, Italy; 5 Ospedale San Giovanni, Rome, Italy; 6 Catholic University of the Sacred Heart, Rome, Italy 443 Cerebrospinal Fluid Markers in Long-Term Atazanavir/Ritonavir Monotherapy Francesca Ferretti ; Alba Bigoloni;Valeria Longo; Laura Galli; Laura Passeri; Simonetta Gerevini;Vincenzo Spagnuolo; Adriano Lazzarin; Paola Cinque; Antonella Castagna San Raffaele Scientific Institute, Milan, Italy 444 Neurocognitive Decline Is AssociatedWith Antiretroviral Concentrations in Plasma and Cerebrospinal Fluid (CSF) Qing Ma 1 ; Xia Liu 2 ; Robert Heaton 1 ; Fujie Zhang 2 ; Hua Jin 1 ; HaoWu 2 ; Melanie Crescini 1 ; Hongxin Zhao 2 ; Hui Zeng 2 ; Scott Letendre 1 1 University of California San Diego, San Diego, CA, US; 2 Chinese Center for Disease Control and Prevention, Beijing, China 445 Viral Decay Rate in the Cerebrospinal Fluid After Initiating Antiretroviral Therapy Natalie M. Bowman 1 ; Sarah B. Joseph; Prema Menezes 1 ; Jessica Margolis 1 ; Christopher Lippincott 1 ; Michael J.Vinikoor 1 ; Kevin R. Robertson 1 ; Richard Price 2 ; Ronald Swanstrom 1 ; Joseph Eron 1 1 University of North Carolina, Chapel Hill, NC, US; 2 University of California San Francisco (UCSF), San Francisco, CA, US 446 Rates of Nonconfounded HIV-Associated Neurocognitive Disorder After Early cART Teresa H. Evering 1 ; Allison Applebaum 2 ; Melissa La Mar 1 ; Donald Garmon 1 ; David Dorfman 3 ; Martin Markowitz 1 1 Aaron Diamond AIDS Research Center, an Affiliate of the Rockefeller University, New York, NY, US; 2 Memorial Sloan-Kettering Cancer Center, New York, NY, US; 3 Mount Sinai School of Medicine, New York, NY, US 447 The Impact of HAART CNS Penetration Effectiveness on Brain Integrity in HIV+ Adults Laurie Baker 1 ; Robert H. Paul 1 ; Jodi M. Heaps 1 ; Mario Ortega 2 ; Christin Usher 1 ; JeeYoon Chang 2 ; Beau Ances 2 1 University of Missouri St Louis, St Louis, MO, US; 2 Washington University School of Medicine, St Louis, MO, US 448 Efavirenz Use is Not Associated with Increased Risk of Neuropsychological Impairment Sean B. Rourke 1 ; John Gill 2 ; Anita Rachlis 1 ; Colin Kovacs 4 ; Gordon Arbess 5 ; Jason Brunetta 4 ; Adriana Carvalhal 1 ; Chris Power 2 ; Ann N. Burchell 3 ;Tsegaye Bekele 3 1 University of Toronto, Toronto, Canada; 2 University of Alberta, Calgary, Canada; 3 The Ontario HIV Treatment Network, Toronto, Canada; 4 Maple Leaf Medical Clinic, Toronto, Canada; 5 St. Michael’s Hospital, Toronto, Canada 449 Quantitative Electroencephalogram as a Translational Biomarker for NNRTI CNS AEs PamelaTannenbaum; Jacquelyn Binns; SpencerTye; Alan Savitz; Steven Fox; Christopher Burgey; Ming-tain Lai; Arthur Simen; daria hazuda; Michael D. Miller Merck and Co, Inc, West Point, PA, US

WEDNESDAY, FEBRUARY 25, 2015 Session P-G3 Poster Session

Poster Hall

2:30 pm– 4:00 pm Neurologic Disorders in Resource-Limited Settings 451 Neurocognitive Impairment in Diverse Resource-Limited Settings: The International Neurological Study ACTG A5199 and A5271 Kevin R. Robertson 1 ; Hongyu Jiang 2 ; Scott Evans 2 ; Christina Marra 4 ; Baiba Berzins 3 ; James Hakim 5 ; Ned Sacktor 6 ;Thomas Campbell 7 ; AnnWalawander 8 ; Jeff Schouten 4 On behalf of ACTG 5199 and 5271 1 University of North Carolina Chapel Hill, Chapel Hill, NC, US; 2 Harvard University, Boston, MA, US; 3 Northwestern University, Chicago, IL, US; 4 University of Washington, Seattle, WA, US; 5 University of Zimbabwe, College of Health Sciences, Harare, Zimbabwe; 6 Johns Hopkins University, Baltimore, MD, US; 7 University of Colorado, Denver, CO, US; 8 Frontier Science, Amherst, NY, US; 9 University of Washington, Seattle, WA, US 452 High Frequency of Dementia in Antiretroviral-Naïve HIV+ Individuals in Rural Uganda Ned Sacktor 1 ; Deanna R. Saylor 1 ; Gertrude Nakigozi 2 ; Noeline Nakasujja 3 ; Xiangrong Kong 4 ; Kevin Robertson 5 ; Ronald H. Gray 4 ; Maria J.Wawer 4 1 Johns Hopkins University School of Medicine, Baltimore, MD, US; 2 Rakai Health Sciences Program, Entebbe, Uganda; 3 Makerere University College of Health Sciences, Kampala, Uganda; 4 Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 5 University of North Carolina, Chapel Hill, NC, US 453 Validation of the International HIV Dementia Scale Screening Tool for HAND in Uganda Megan M. Hosein 1 ; Deanna Saylor 1 ; Gertrude Nakigozi 2 ; Noeline Nakasujja 3 ; Xiangrong Kong 4 ; Kevin Robertson 5 ; Ronald H. Gray 4 ; Maria J.Wawer 4 ; Ned Sacktor 1 1 Johns Hopkins University School of Medicine, Baltimore, MD, US; 2 Rakai Health Sciences Program, Kalisizo, Uganda; 3 Makerere University College of Health Sciences, Kampala, Uganda; 4 Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 5 University of North Carolina Chapel Hill, Chapel Hill, NC, US 454 Cerebrospinal Fluid Cytokines and HIV-Associated Neurocognitive Disorders in Uganda Mahsa Abassi 1 ; Gertrude Nakigozi 3 ; Noeline Nakasujja 2 ; Xiangrong Kong 4 ; David B. Meya 2 ; Kevin Robertson 5 ; Ronald H. Gray 4 ; Maria J.Wawer 5 ; Ned Sacktor 5 ; David R. Boulware 1 1 University of Minnesota, Minneapolis, MN, US; 2 Infectious Disease Institute, Kampala, Uganda; 3 Rakai Health Sciences Program, Entebbe, Uganda; 4 Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 5 Johns Hopkins University School of Medicine, Baltimore, MD, US 455 A Comparison of 5 Brief Screening Tools for HAND in the USA and South Africa John A. Joska 1 ; JadeWitten 1 ; KevinThomas 1 ; Corne Robertson 1 ; Martine Casson-Crook 1 ; Heidi Roosa 2 ; Jason Creighton 2 ; Jennifer Lyons 3 ; Justin McArthur 2 ; Ned Sacktor 2 1 University of Cape Town, Cape Town, South Africa; 2 Johns Hopkins University School of Medicine, Baltimore, MD, US; 3 Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, US 456 Subtype Associations With HIV-Associated Neurocognitive Dysfunction Tyler R. Day ; Davey M. Smith; Robert Heaton; Donald Franklin; MyresW.Tilghman; Josué Pérez-Santiago University of California San Diego, San Diego, CA, US

Poster Listings

39

CROI 2015